(S (PP (IN In) (NP (NP (NN line)) (PP (IN with) (NP (NP (JJ recent) (NNS advances)) (PP (IN in) (NP (NML (JJ neural) (NN drug)) (NML (NN design) (CC and) (NN sensitivity)) (NN prediction))))))) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (DT a) (JJ novel) (NN architecture)) (PP (IN for) (NP (NP (ADJP (JJ interpretable)) (NN prediction)) (PP (IN of) (NP (NP (JJ anticancer) (NN compound) (NN sensitivity)) (VP (VBG using) (NP (DT a) (JJ multimodal) (ADJP (NN attention) (HYPH -) (VBN based)) (JJ convolutional) (NN encoder)))))))) (. .))
(S (NP (PRP$ Our) (NN model)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (NP (NP (DT the) (CD three) (JJ key) (NNS pillars)) (PP (IN of) (NP (NN drug) (NN sensitivity)))) (: :) (NP (NP (NP (NNS compounds) (POS ')) (NN structure)) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (DT a) (NN SMILES) (NN sequence))))))) (, ,) (NP (NP (NN gene) (NN expression) (NNS profiles)) (PP (IN of) (NP (NNS tumors)))) (CC and) (NP (NP (JJ prior) (NN knowledge)) (PP (IN on) (NP (JJ intracellular) (NNS interactions)))))) (PP (IN from) (NP (NML (NN protein) (HYPH -) (NN protein)) (NN interaction) (NNS networks))))) (. .))
(S (NP (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (PRP$ our) (ADJP (NP (JJ multiscale) (JJ convolutional) (NN attention)) (HYPH -) (VBN based) (PRN (-LRB- -LRB-) (NP (NNP MCA)) (-RRB- -RRB-))) (NN encoder)) (ADVP (RB significantly)) (VP (VBZ outperforms) (NP (NP (NP (DT a) (NN baseline) (NN model)) (VP (VBN trained) (PP (IN on) (NP (NP (NNP Morgan) (NNS fingerprints)) (, ,) (NP (NP (DT a) (NN selection)) (PP (IN of) (NP (NNS encoders)))))) (PP (VBN based) (PP (IN on) (S (VP (VBZ SMILES))))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (ADJP (RB previously) (VBN reported)) (NN state)) (PP (IN of) (NP (NP (DT the) (NN art)) (PP (IN for) (NP (JJ multimodal) (NML (NN drug) (NN sensitivity)) (NN prediction) (PRN (-LRB- -LRB-) (S (S (NP (NN R2)) (VP (SYM =) (NP (CD 0.86)))) (CC and) (S (NP (NN RMSE)) (VP (SYM =) (NP (CD 0.89))))) (-RRB- -RRB-)))))))))))) (. .))
(S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN explainability)) (PP (IN of) (NP (PRP$ our) (NN approach)))) (VP (VBZ is) (VP (VBN demonstrated) (PP (IN by) (NP (NP (DT a) (JJ thorough) (NN analysis)) (PP (IN of) (NP (DT the) (NN attention) (NNS weights))))))) (. .))
(S (NP (PRP We)) (VP (VBP show) (SBAR (SBAR (IN that) (S (NP (DT the) (ADJP (VBN attended)) (NNS genes)) (ADVP (RB significantly)) (VP (VBP enrich) (NP (JJ apoptotic) (NNS processes))))) (CC and) (SBAR (IN that) (S (NP (DT the) (NN drug) (NN attention)) (VP (VBZ is) (ADVP (RB strongly)) (VP (VBN correlated) (PP (IN with) (NP (DT a) (JJ standard) (NML (JJ chemical) (NN structure)) (NN similarity) (NN index))))))))) (. .))
(S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (DT a) (NN case) (NN study)) (PP (IN of) (NP (NP (CD two) (NML (NN receptor) (NN tyrosine) (NN kinase) (-LRB- -LRB-) (NN RTK) (-RRB- -RRB-)) (NNS inhibitors)) (VP (VBG acting) (PP (IN on) (NP (DT a) (NML (NN leukemia) (NN cell)) (NN line))) (, ,) (S (VP (VBG showcasing) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT the) (NN model)))) (S (VP (TO to) (VP (VB focus) (PP (IN on) (NP (NP (JJ informative) (NNS genes)) (CC and) (NP (NP (JJ submolecular) (NNS regions)) (PP (IN of) (NP (DT the) (CD two) (NNS compounds)))))))))))))))) (. .))
(S (NP (NP (DT The) (VBN demonstrated) (NN generalizability)) (CC and) (NP (NP (DT the) (NN interpretability)) (PP (IN of) (NP (PRP$ our) (NN model))))) (VP (VB testify) (NP (PRP$ its) (NN potential)) (PP (IN for) (NP (NP (NML (PP (IN in) (HYPH -) (NP (FW silico)))) (NN prediction)) (PP (IN of) (NP (NP (JJ anticancer) (NN compound) (NN efficacy)) (PP (IN on) (NP (JJ unseen) (NN cancer) (NNS cells))))))) (, ,) (S (VP (VBG positioning) (NP (PRP it)) (PP (PP (IN as) (NP (NP (DT a) (JJ valid) (NN solution)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (VBN personalized) (NNS therapies))))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (NP (NN candidate) (NNS compounds)) (PP (IN in) (NP (ADJP (FW de) (FW novo)) (NN drug) (NN design))))))))))) (. .))
